Pharma BD Deal Intelligence
A $464M tuck-in that became the molecular backbone of Gilead's HIV empire — emtricitabine went into Truvada, Atripla, Stribild, Genvoya, Descovy and Biktarvy, generating tens of billions in cumulative revenue.
Full analysis, sources & comparables →Gilead announced definitive agreement to acquire Triangle for ~$464M at $6.00/share cash, framing Coviracil (emtricitabine) as core to a fixed-dose combination…
Gilead's acquisition of the struggling Triangle Pharmaceuticals resolved months of uncertainty surrounding Triangle's viability and the commercial prospects of…
Gilead and Royalty Pharma paid Emory University $525M for the emtricitabine royalty interest in 2005 — a transaction that valued the single asset higher than…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Gilead Sciences acquired Triangle Pharmaceuticals for approximately $464 million in cash at $6.00 per share, announced December 4, 2002 via a two-step tender offer that completed in January 2003. The acquisition brought Gilead emtricitabine (later marketed as Emtriva), central to its fixed-dose HIV combination strategy with Viread.
A $464M tuck-in that became the molecular backbone of Gilead's HIV empire — emtricitabine went into Truvada, Atripla, Stribild, Genvoya, Descovy and Biktarvy, generating tens of billions in cumulative revenue.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. (this deal) | 2002 | $464M | 96 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
| Gilead Sciences Inc. / Myogen Inc. | 2006 | $2.5B | 62 |
← Browse all deals · How we score deals
More: 2002 deals · Gilead Sciences Inc. deals